Great strides in gene discovery have been made using a multitude of methods to associate phenotypes with genetic variants, but there still remains a substantial gap between observed symptoms and identified genetic defects. Herein, we use the convergence of various genetic and genomic techniques to investigate the underpinnings of a constellation of phenotypes that include prostate cancer (PCa) and sensorineural hearing loss (SNHL) in a human subject. Through interrogation of the subject's de novo, germline, balanced chromosomal translocation, we first identify a correlation between his disorders and a poorly annotated gene known as lipid droplet associated hydrolase (LDAH). Using data repositories of both germline and somatic variants, we identify convergent genomic evidence that substantiates a correlation between loss of LDAH and PCa. This correlation is validated through both in vitro and in vivo models that show loss of LDAH results in increased risk of PCa and, to a lesser extent, SNHL. By leveraging convergent evidence in emerging genomic data, we hypothesize that loss of LDAH is involved in PCa and other phenotypes observed in support of a genotype-phenotype association in an n-of-one human subject.
Introduction
Decreasing costs of genomic sequencing have led to a rapidly expanding catalog of both pathogenic and benign variants associated with human traits and disorders, making it possible to envision genome-informed personalized medicine. Nonetheless, determining pathogenicity of variants in individuals remains a daunting challenge. Rare variants are often attractive targets because they may be analyzed under a monogenic model. However, small sample size, incomplete penetrance and background biases make it difficult to impute the impact of these novel variants to the general population (1) . On the opposite end of the spectrum, genome-wide association studies (GWASs) have established the correlation between hundreds of common variants and common diseases; however, these common variants tag loci with diminishingly small and uncertain effects and only explain a fraction of human heritability (2) (3) (4) . However, the genetic impact of n-of-one studies has been increasingly elucidated through leveraging the mutual intersection of monoand poly-genetic studies (4) (5) (6) .
In this study, we employed a convergent genomic approach to identify an association between reduced expression of a poorly annotated gene, known as lipid droplet associated hydrolase (LDAH), and a syndromic phenotype in a single individual. Through the Developmental Genome Anatomy Project (DGAP, www.dgap.harvard.edu), we first identified a putative association of LDAH with prostate cancer (PCa) and sensorineural hearing loss (SNHL) in a human subject (DGAP056) with a de novo germline balanced chromosomal abnormality (BCA). We then amassed convergent genomic evidence showing population level associations between LDAH expression and occurrence of PCa. We further identified loss of LDAH in both tissues and cell lines derived from human PCa, and generated a Ldah -/-mouse model, which recapitulated many of the clinical findings in DGAP056. This investigation elucidates a causal correlation between reduced expression of LDAH and PCa in in vivo and in vitro studies in both humans and mice.
Results

Association of loss of LDAH expression due to a de novo variant with early onset PCa
DGAP056 first presented with a constellation of congenital abnormalities including profound SNHL, craniofacial dysmorphism, hypospadias and mitral valve prolapse. During the course of this study, DGAP056 was diagnosed with PCa at age 38 years, over two standard deviations below the mean age-of-diagnosis at 70 years ( Fig. 1 and Supplementary Material, Fig. S1 ), resulting subsequently in a radical prostatectomy (see detailed history in Supplementary Information). Histological sections from DGAP056's formalin-fixed paraffin-embedded prostate tissue block were haematoxylin and eosin (H&E) stained to visualize abnormal structure (Fig. 1A) . Hyperplasia within several glands containing prominent nucleoli was observed in concert with the histopathology report. Given the multiple congenital anomalies and early-onset PCa, we explored the possibility of a genetic germline origin of the phenotype in DGAP056. Upon enrollment at 21 years of age, DGAP056's karyotype was interpreted as 46,XY,t(2;13)(p24;q21)dn, indicating an apparently balanced de novo chromosome translocation. Chromosomal breakpoints were mapped using fluorescence in situ hybridization (FISH) with a series of probes of labeled bacterial artificial chromosome (BAC) clones. FISH with BAC RP11-310O5, which localizes to 2p24.1, hybridized to the normal chromosome 2, the der(2) and the der (13) (Fig. S2) . Likewise, BAC RP11-19D22, which localizes to 13q22.2-q22.3, hybridized to the normal chromosome 13, the der(13) and the der(2) (Data not shown). These split BACs refined the translocation breakpoints to 2p24.1 and 13q22.2-q22.3. Sanger sequencing further resolved the (2) (top) and der(13) (bottom) chromosomes with Sanger sequencing chromatographs of breakpoints disrupting LDAH (HGNC:26145, previously designated as FLJ21820 and C2orf43). Segments containing chromosomes 2 (purple) or 13 (orange) sequence are indicated. Red boxes indicate positions shown in higher resolution at the genic and nucleotide levels. Nucleotides of breakpoints are noted along with a 68 bp insertion of nontemplated sequence (nucleotides in black lettering) in the der (2) and microhomology (nucleotides delineated with curly brackets) in the der(13).
breakpoints to nucleotide level and, using Next-Generation Cytogenetic Nomenclature (7), the karyotype is defined as follows: 46,XY,t(2;13)(p24. (20, 913, 647 )->2qter; 13pter->13q22.2(77,172,04{5-9})::2p24.1 (20, 913 ,6{43-39})->2pter) dn (Fig. 1B) .
This karyotype indicates that no annotated genes were disrupted in the region of the chromosome 13 breakpoint; however, the chromosome 2 breakpoint disrupts the poorly annotated gene encoding LDAH.
To determine the functional effect of the chromosome translocation, LDAH transcription was evaluated in an EpsteinBarr virus-immortalized B-lymphoblastoid cell line (LCL) derived from DGAP056's whole blood. Rapid amplification of cDNA ends (RACE) reveled both the normal full-length LDAH transcript (ENST00000237822.7) as well as two novel abnormal transcripts (Supplementary Material, Fig. S3A ). Quantitative analysis of these transcripts showed reduced expression of the full-length LDAH transcript (Supplementary Material, Fig. S3B ). Western blot analysis of protein extracted from DGAP056's LCL showed a reduction in normal LDAH protein, but no abnormal protein products were discernable (Supplementary Material, Fig. S3C ). The reduced expression at both RNA and protein levels suggests a haploinsufficiency effect from disruption of a single coding LDAH allele in the etiology of DGAP056's phenotype including the early-onset PCa.
Association of a common germline variant in PCa populations with loss of LDAH
To investigate a relationship between LDAH disruption and PCa, we interrogated population level association studies between germline genomic variation and abnormal phenotypes using public databases. Multiple disease associating genetic databases, including several GWASs, were integrated into browser extensible data and visualized in the University of California Santa Cruz Genome Browser using the human GRCh37/hg19 reference file in the linkage-disequilibrium (LD) region of European ancestry for LDAH (Chr2:20,849,778-21,052,988; Supplementary Material, Fig. S4 ) (8, 9) . The LD block for LDAH was notable for a variety of reported traits (e.g. low-density lipoprotein, cholesterol levels, triglyceride levels, lymphocyte counts, digit-length ratio and brachial arm circumference). Nominal genome-wide significance for PCa was identified for SNP rs13385191 G, which is located between exons 6 and 7 of the full-length LDAH transcript (NM 021925.3, Fig. 2A and Supplementary Material, Fig. S4 ) (10) . A systematic analysis of mapped genetic association studies and the literature revealed six other GWASs or candidate association studies in European, Chinese and African populations that examined association of this locus with PCa (11) (12) (13) (14) (15) (16) . Of these seven studies, five examined the association between the rs13385191 locus and a PCa diagnosis, while two examined associations with more aggressive forms of PCa. A retrospective meta-analysis was performed stratifying these studies on a diagnosis of PCa and aggressive PCa. While the aggressive PCa studies did not meet genome-wide significance of disease association, genome-wide significance (P = 2.1e-08) was observed between the risk allele (rs13385191 G) and the diagnosis of PCa with a combined increased odds ratio (OR) of 1.17 [95% confidence interval (CI), 1.12-1.23; Fig. 2A] . The metaanalysis reported herein confirms previous studies showing genome-wide significance in the association of LDAH variants with PCa.
To determine the risk allele's association with changes in expression levels of LDAH, the expression quantitative trait locus (eQTL) of rs1338191 was assessed in normal prostate tissues (n = 87) in the Genotype-Tissues Expression (GTEx) database. These data show that subjects carrying both copies of the PCa risk allele (rs13385191 G) had significant specific downregulation of LDAH (P = 5.0e-5) in their prostates compared to subjects homozygous for the reference allele (rs13385191 A) (Fig. 2B) . The combined GWAS and eQTL data corroborated the findings in DGAP056, substantiating that both measures of population-level variants associated with downregulation of LDAH correlate with an increased risk of PCa. Similar to the majority of GWAS alleles, the rs13385191 G risk allele has a small, but significant increase in PCa risk (OR = 1.17). 
Association of somatic mutations in PCa with loss of LDAH expression
We next investigated whether the relationship between LDAH and PCa in germline tissues extends to somatic mutations in prostate tumors. Initial analysis from The Cancer Genome Atlas showed no significant increase of prostate-specific somatic mutations or copy number alterations in LDAH exons. This analysis was then extended to the entire regulatory region of LDAH using the plexus reoccurrence test (PRT) (17) . Using whole genome sequencing data from adenocarcinomas compared to adjacent benign prostate tissue (n = 55), a 10-fold significant enrichment (P = 0.004) of somatic mutations in LDAH regulatory regions was observed in adenocarcinoma tissue (Fig. 2C ). This significant increase in somatic mutations in regulatory regions suggests that dysregulation of LDAH in prostate tumors is common.
To determine if these genomic changes are related to a functional effect, we examined changes in LDAH levels in prostate tumor tissues. Starting with expression data deposited in the Gene Expression Omnibus (GEO) from four of the largest microarray analysis studies of PCa, LDAH differential expression was analyzed from both benign and tumor samples (18) (19) (20) (21) . All studies consistently show significant down-regulation of LDAH in primary tumors, with a combined z-score mean = −0.84 (P = 6.1e-14) ( Fig. 2D and Supplementary Material, Fig. S5 ). LDAH down-regulation was even more dramatic in metastatic tumors, which had significantly less expression than either benign (combined z-score mean = −3.9; P = 4.2e-43) or primary tumor tissues (P = 2.0e-30). Cross comparison across the entire shared gene set showed that LDAH was one of the most frequently down-regulated genes (z-score ≤ −2.0) in both primary (9 We also investigated the relationship of LDAH expression with PCa morbidity (Fig. 2F ). Using the aforementioned PCa microarray data, disease-free survival times in subjects with significant down-regulation (z ≤ −2) of LDAH was compared to those with normal or elevated LDAH expression. This analysis revealed a significantly shortened interval (hazard ratio = 1.71; P = 0.013) in cancer-free survival in subjects with reduced LDAH expression in their prostate tumors, suggesting that not only is LDAH reduction associated with the presence of PCa, but may also have an association with severity of disease. Given convergent genomic evidence observed in rare germline, common germline and recurrent somatic variants, it appears highly likely that loss of LDAH is pathogenic in PCa.
LDAH levels are reduced in prostate tumor tissues
For a more direct examination of LDAH in neoplasia, we examined changes to LDAH protein levels in prostate tissue cores from histologic sections of both benign and tumor tissues ( Fig. 3A and B) . In benign cores, a high percentage of luminal epithelial cells show positive punctate cytoplasm with LDAH immunostaining (46.5%), which was not observed in surrounding stroma. In tumor cores, a significant reduction in the percentage of epithelial cells shows this positive immunostaining (4.57%, P = 1.17e-22). Consistent with the transcriptional changes observed in the microarrays, histologic staining suggests loss of LDAH is a frequent occurrence in prostate tissue and further localizes this loss to luminal epithelial cells, which are the cells most likely to give rise to prostate adenocarcinoma (22) . Akin to our genomic analysis, these studies indicate that prostate tumors have a reduced level of LDAH.
Similar to prostate histological studies, we analyzed LDAH expression levels in cell lines derived from both benign and neoplastic prostate tissues. We extracted both RNA and protein from eight independent prostate-derived cell lines with various oncogenic properties ( Fig. 3C and Supplementary Material, Table S1 ). PC3 cells, the most tumorigenic prostate cell line, had significantly lower (P < 0.05) LDAH transcript and protein levels when compared to the non-tumorigenic prostate cell line RWPE1. This reduction of LDAH expression and protein correlates with increased tumorigenicity of the cell lines with a marked reduction in every tumorigenic cell line compared to RWPE1 cells. In contrast, RWPE1 cells show high levels of LDAH protein and transcript levels. This endogenous reduction of LDAH expression suggests that loss of LDAH is a characteristic of the biology in prostate tumors.
LDAH suppression increases tumorigenicity in prostate cell lines
To determine whether loss of LDAH expression has a direct effect on tumorigenicity, we analyzed several prostate cell lines taking advantage of their differential LDAH expression (Fig. 3D-I) . For RWPE1 cells, a non-tumorigenic cell line with a high level of expression of LDAH, transient silencing of LDAH transcripts, using shRNA, resulted in significant increased proliferation (1.5-fold, P < 0.001) within 4 days of transfection. Interestingly, this increase in proliferation were not accompanied by any change in migration or invasion. We then used PC3 cells, a highly tumorigenic cell line with a low level of LDAH expression, to overexpress LDAH using a stable transfection vector. Overexpression of LDAH resulted in significantly decreased proliferation (P < 0.001) within 7 days of transfection. Furthermore, overexpression of LDAH in PC3 cells significantly reduced migration and invasion (P < 0.05 in all studies) effectively reducing some of the tumorigenic properties of PC3 cells. These in vitro data further implicate a causal role of LDAH in PCa, confirming the association between reduced LDAH expression and PCa observed in DGAP056, association studies and somatic mutations in prostate tumors.
Ldah
-/-mice develop PCa, SNHL and higher body mass in all three lobes of the prostate whereas lesions in Ldah +/+ were lower-grade (mPIN I-II) and restricted to the AP lobe. More impressively, 10% of Ldah -/-mice had invasive prostate lesions, which were found exclusively in the Ldah -/-dorsolateral lobe, which is the mouse lobe most similar biochemically to human prostate (Supplementary Material, Table S2 ) (27) . The Ldah -/-mouse model showed that loss of Ldah expression significantly increases the probability of developing PCa.
Discussion
In this study, we show that loss of LDAH is linked to increased risk of PCa as well as SNHL. We first identified the association of LDAH with these symptoms in a gene discovery experiment by analyzing a de novo germline BCA in a human subject, DGAP056. Through resolving this chromosomal translocation to nucleotide level and performing expression assays, we were able to incriminate LDAH in DGAP056's disorder. However, given no other familial carriers of this BCA and the low probability of finding a similar BCA in the greater population, it was not possible to determine the statistical likelihood of this association. To overcome this hurdle, we turned to large genomic datasets to determine if there was convergent data correlating the loss of LDAH to any of the observed phenotypes. Analyses of both GWAS and eQTL indicate that a common variant rs13385191 at the LDAH locus is associated with a down-regulation of LDAH and a significant association with PCa in multiple genetic backgrounds. Further analysis of both prostate tissues and cell lines showed a positive correlation between tumorigenic tissues and LDAH downregulation. As a whole, this represents four independent lines of evidence from forward-genetic studies (i.e. rare de novo disruption of LDAH in DGAP056 with PCa, significant association of a common variant at the LDAH locus and consistent eQTL in GWAS, down-regulation in prostate tumor tissues and downregulation in PCa cell lines) that all converge on an association between down-regulation of LDAH and increased risk PCa, implicating a role of LDAH in PCa tumor suppression.
To validate this hypothesis, we investigated the consequences of disruption of LDAH in two independent reversegenetic experiments. First, we investigated changes to LDAH in vitro, which showed that reduced expression in benign human prostate cell lines showed increased rates of proliferation, while increasing expression in tumorigenic cell lines showed protection against both proliferation and migration. Second, we investigated the effect of Ldah knockout in vivo, which showed increased rate of mPIN, an early precursor to PCa, (29) . Interestingly, there appeared to be a sex dependence in both traits, as SNHL was more dramatic in males and increased body mass was only significant in females. Contrary to our observations, Kory et al. (30) also report the generation of an Ldah -/-mouse model, but fail to report any significant observations, which may be attributed to the fact that none of the phenotypes measured in this study (i.e. PCa, SNHL and body weight) were interrogated to the same degree.
Further interrogation of these in vitro and in vivo models will be important for deciphering the functional consequence of changes in LDAH especially given that the function of LDAH is still unknown. While it has been shown that LDAH co-localizes with lipid droplets, the function of this protein is currently debated (31) . Five studies have now investigated the molecular function of LDAH with inconsistent findings (30, (32) (33) (34) (35) . Goo et al. (33, 35) found that in both macrophages and human embryonic kidney (HEK) cells, LDAH acts as a cholesteryl esterase at the surface of lipid droplets. However, Thiel et al. (32) , Kory et al. (30) and Kolkhof et al. (34) contest the possibility of LDAH acts as a cholesteryl esterase. While Kory et al. (30) were unable to identify any functional consequences due to loss of LDAH, Theil et al. (32) and Kolkhof et al. (34) observe changes to lipid droplet architecture without any discernable lipid metabolism change, leading them to postulate that LDAH likely acts more as an acyltransferase, modifying phospholipids or an interaction hub in lipid droplets. In our studies, we found no evidence to either support or contradict the metabolic function of LDAH, but the localization to lipid droplets and putative role in lipid metabolism is intriguing as prostate tumorigenesis, hearing loss and obesity are associated with lipid dysregulation (36) (37) (38) . Establishing the function of LDAH should help gain insight into this lipid oncogenic mechanism.
Given the cumulative evidence, our interpretation is that loss of LDAH increases the risk of PCa and may have other pleiotropic effects including SNHL. Its pathogenicity likely operates through haploinsufficiency in a lipid metabolic pathway contributing to the abnormal phenotype in DGAP056. Although the mouse phenotype attributed to Ldah knockout shows a later onset hearing loss, mouse models are not uncommonly less resistant to haploinsufficiency than humans and show variable expression. Furthermore, the mouse prostate is extremely resistant to metastatic cancer. A polygenic etiology could also be at play given the genetic complexity of both PCa and SNHL, and it is possible that the genetic background of DGAP056 and/or other genes dysregulated by the translocation could impact the phenotype.
Of note in this regard, targeted exome sequencing of hearing loss genes was negative for pathogenic variants, although such tests are limited by our knowledge of an incomplete catalog of genes for hearing. Nonetheless, whether the complex DGAP056 phenotype is the result of simple haploinsufficiency or polygenic effects, the abundance of evidence argues in support of a loss of LDAH expression as a risk for both PCa and SNHL.
In summary, we report that loss of LDAH results in higher risk of developing PCa, which was first identified using a convergent genomics approach and then verified both in vitro and in vivo models. We propose that the Ldah -/-mouse model will facilitate further investigations into the role of LDAH in lipid biology and help define the molecular mechanism involved in tumor initiation and metastasis during prostate oncogenesis. The LDAH pathway may be a new potential target for treatment of PCa.
Materials and Methods
Human subject
DGAP056 was enrolled in the DGAP under the Partners HealthCare System Internal Review Board (IRB) protocol number 1999P003090. Karyotyping was performed on leukocytes collected from DGAP056, using GTG-banding per standard protocols. An LCL was generated from DGAP056 peripheral blood as a source for all additional DNA, RNA and protein assays. FISH was performed on metaphase chromosomes from at least 10 cells prepared from DGAP056 and control LCLs using BACs directly labeled with either SpectrumOrange-or SpectrumGreen-conjugated nucleotides by nick translation, and differently labeled pairs were hybridized to metaphase chromosomes per standard protocols and analyzed with Cytovision (39) . Translocation breakpoints were further refined by restriction endonuclease cleavage mapping and targeted with radioactively labeled probes on southern blots. Putative DGAP056 breakpoints were screened using a suppression PCR strategy and confirmed with Sanger sequencing of the region to achieve breakpoint resolution (40) . Chromosomal breakpoints are described using Next-Generation Cytogenetic Nomenclature obtained by BLA(S)T Output Sequence Tool of Nomenclature (7). Unique RNA transcripts were analyzed by performing the 3'-RACE reactions and gel-purified products were Sanger sequenced. 
Custom-made anti-LDAH antibody, tissue microarrays and immunohistochemistry
Mouse model generation
Ldah -/-mouse models were generated using a homologous 
Mouse physiology and histology
Mice were evaluated for differences in body weight, cochlear function and prostate histology based on initial gross observations and/or suspected phenotypes based on human subject studies. Ldah -/-and Ldah +/+ littermate mice were weighed on a digital scale the first week of every month to determine body mass, and weight-over-time was analyzed for each mouse, sex and genotype, trimmed for outliers using the Robust Regression and Outlier algorithm, and compared using the extra sum-ofsquares F-test (41) . Mouse auditory evaluations were performed using both distortion-product otoacoustic emissions (DPOAEs) and ABRs in Ldah -/-and in Ldah +/+ littermates to assess cochlear and auditory neural function. Data from ears were only used in final analyses if both ABRs and DPOAEs were performed and cochlea was normal on visual and histological inspection. We assessed statistical significance with two-way ANOVA (genotype, frequency), and as no interaction effects were significant, only the main effect of interest (i.e. genotype) is reported. For histology, prostate tissues were microdissected to isolate AP, VP and DLP lobes, placed in labeled cassettes and fixed in 10% formalin for at least 24 h, followed by paraffin-embedding, sectioning and H&E-staining of a subset. Two independent pathologists examined H&E-and Ki-67-stained prostate lobes for each mouse and graded them using a system based on Shappell et al. (25) and Park et al. (26) to score the lobe as either prostatic intraepithelial neoplasia (mPIN, with sub-grading to mPIN I-IV), microinvasive or invasive lesion(s) (25) . The most advanced lesion for each lobe was used in the statistical calculations.
Western blots and qPCR
For western blots, protein was extracted by suspending tissues or cells in cold radioimmunoprecipitation assay buffer and protease inhibitor, homogenized and centrifuged (15 000 
GWAS, eQTL, microarray and PRT analysis
Data for meta-analysis of genetic studies were curated by searching PubMed using the following terms: LDAH, C2orf43, FLJ21820, UPF0554 and 1110057K04Rik (last accessed June 2017). Search results were perused to identify association studies with any genetic markers. Meta-analysis was performed using a fixed effects inverse variance model. For eQTL data were acquired for 87 prostate samples from GTEx (www.gtexportal.org) and eQTL analysis performed using the MatrixEQTL R package (42 For meta-analysis of PCa expression arrays, data were curated from GEO by filtering for large prostate datasets that compared non-laser captured microarray expression analysis. A custom R script was used to adjust for skew in reported results (using log 2 correction where needed) and quantile normalized (43, 44) . LDAH quantile normalized values were used to calculate z-values within each study, for cross-platform comparisons and to rank order differential expression across the entire genome. For the PRT, the gene plexus uses a set of genomic elements to define regions that affect the gene's function (17) . In brief, the normal prostate plexus for LDAH is generated by defining a unique set of tiles (based on chromatin state, Hi-C data, transcription start site and exons) based on a local expectation of interaction frequency representing all of the proximal and distal elements that impinge on a gene's function. This plexus was used to retrieve tumor mutations from 55 whole genome tumor-normal pairs for prostate adenocarcinoma from the GTEx repository. The PRT permutation-based algorithm estimates the expected number of mutations for a gene's plexus and computes an enrichment score and P-value for statistical significance of positive selection. We performed three independent tests in the LDAH plexus for promoter, dyadic and enhancer classes of regulatory elements, with P-values of 0.004, 0.023 and 0.492, respectively.
Supplementary Material
Supplementary Material is available at HMG online.
